Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

29P - Outcomes of patients with intermediate-high risk early stage endometrial cancer after surgery according to adjuvant treatment

Date

23 Feb 2023

Session

Poster Display session

Presenters

leticia vecchi leis

Citation

Annals of Oncology (2023) 8 (1suppl_1): 100792-100792. 10.1016/esmoop/esmoop100792

Authors

L. vecchi leis1, R. Colombo Bonadio1, F. Peres de Oliveira Ferreira1, B. Zanin Orsi1, S. Vidaurre Mendes2, A.P. Messias1, J.M. Vasconcellos1, O.A. Moreira1, A. Rodrigues de Araujo Neto1, M. Baptista Pereira1, M.D.P.E. Diz2

Author affiliations

  • 1 ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo/BR
  • 2 ICESP - Instituto do Cancer do Estado de Sao Paulo, 01246-000 - Sao Paulo/BR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 29P

Background

Management of intermediate-high risk early stage endometrial cancer (EC) can be challenging since a proportion of these patients (pts) relapse and the role of adjuvant chemotherapy (CT) is unclear. We aimed to evaluate the role of adjuvant CT for this population.

Methods

This retrospective study evaluated pts with intermediate-high risk early stage EC treated in a single center from 2009 to 2021. Endpoints were overall survival (OS) and disease free survival (DFS) according to the adjuvant systemic treatment used after surgery. The Kaplan-Meier method was used for survival analyses. Hazard ratio (HR) and 95% confidence interval (95% CI) were calculated using Cox regression.

Results

175 pts were evaluated and median age was 63 years (IQR 34-88). About the risk category, 33% had stage I disease with lymphovascular invasion (LVI); 22% had stage IB with grade 3 disease and 43% had stage II disease. Regarding surgery, 144 pts (82%) were submitted to pelvic and 107 (61%) to paraortic lymphadenectomy. 41 pts (29%) received CT (96% carboplatin and paclitaxel), 37 (21%) received adjuvant external beam radiotherapy (EBRT), 37 (21%) received adjuvant brachytherapy (BCT), and 77 (44%) received both EBRT and BCT. With a median follow-up of 64 months, 33 pts had a disease recurrence; 10% had a locoregional recurrence, 7% a distant recurrence, and 2% had both locoregional and distant recurrence. No difference was observed in DFS or OS according to the use of adjuvant CT. 5-year DFS rates were 74.7% (95% CI 64.7 - 82.2%) in those who received CT and 77% (95% CI 62.3- 86.6%) in pts who did not received CT (p = 0.392). 5-year OS were 87.1% (95% CI 78.2 - 92.5%) in and 93.3% (95% CI 80.6 - 97.8%), respectively (p = 0.259). BCT (HR 0.36, 95% CI 0.18 - 0.68, P=0.002) and pelvic lymphadenectomy (HR 0.42, 95% CI 0.21 - 0.83, P=0.014) were identified as factors associated with a superior DFS, while FIGO stage II (HR 2.17, 95% CI 1.12 - 4.22, P=0.021) was associated with inferior DFS. Pts that received BCT had less locoregional recurrence than those who did not receive it (4,4% vs 10,3%).

Conclusions

Pts with intermediated-high risk early stage EC does not seem to benefit from adjuvant CT. In this cohort, BCT and pelvic lymphadenectomy were associated with a better DFS.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.